23 results
8-K
EX-99.1
ADVM
Adverum Biotechnologies Inc
18 Mar 24
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates
4:08pm
of experience in drug development, including leading Spark Therapeutics’ translational R&D for Luxturna®, a subretinal injection gene therapy product
8-K/A
ADVM
Adverum Biotechnologies Inc
4 Dec 23
Departure of Directors or Certain Officers
4:09pm
and Forest Laboratories, Inc.) as Senior Vice President, Actavis Global Brands R&D, in August 2014. Prior to Allergan, from March 2012 to July 2014, Dr
8-K
ADVM
Adverum Biotechnologies Inc
6 Nov 23
Departure of Directors or Certain Officers
4:10pm
joined Allergan (previously known as Actavis plc and Forest Laboratories, Inc.) as Senior Vice President, Actavis Global Brands R&D, in August 2014
PRE 14A
ejo2 e0vhwtu9jr
14 Apr 23
Preliminary proxy
6:03am
8-K
EX-99.1
n8537mt62858li97o1
30 Mar 23
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Phase 2 LUNA Trial Update
4:09pm
8-K
q7r8mbbkj9tuza06w8
24 Jun 21
Departure of Directors or Certain Officers
4:16pm
DEFA14A
k2o 3t596cpkkokh
15 Apr 21
Additional proxy soliciting materials
8:59am
DEFC14A
qtlslrtvzid
15 Apr 21
Proxy in contested solicitation
6:03am
PRER14A
ak0c9l 8zi
7 Apr 21
Preliminary revised proxy
4:28pm
PREC14A
n9ka5 j1lv
5 Apr 21
Preliminary proxy with contested solicitation
5:27pm
DEFA14A
nwgykdgnbkregn119i
17 Mar 21
Additional proxy soliciting materials
9:55pm
DEFA14A
ythyl ed7u
17 Mar 21
Additional proxy soliciting materials
5:28pm
8-K
mxk bv56j
14 Oct 16
Adverum Biotechnologies, Inc. Announces New Executive Chair and CEO
12:00am
8-K
EX-99.1
pgkdvnxst
14 Oct 16
Adverum Biotechnologies, Inc. Announces New Executive Chair and CEO
12:00am